{"id":1915,"date":"2025-06-26T16:43:27","date_gmt":"2025-06-26T19:43:27","guid":{"rendered":"https:\/\/www.pint-pharma.com\/portal\/?p=1915"},"modified":"2025-06-26T16:45:16","modified_gmt":"2025-06-26T19:45:16","slug":"pint-pharma-announces-invimas-approval-of-orladeyo-berotralstat-the-first-oral-therapy-for-preventing-hereditary-angioedema-hae-attacks-in-patients-aged-12-and-older-in-colombia","status":"publish","type":"post","link":"https:\/\/www.pint-pharma.com\/portal\/pint-pharma-announces-invimas-approval-of-orladeyo-berotralstat-the-first-oral-therapy-for-preventing-hereditary-angioedema-hae-attacks-in-patients-aged-12-and-older-in-colombia\/","title":{"rendered":"Pint Pharma Announces INVIMA\u2019s Approval of ORLADEYO\u00ae (berotralstat), the First Oral Therapy for Preventing Hereditary Angioedema (HAE) Attacks in Patients Aged 12 and Older in Colombia"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Pint Pharma Announces INVIMA\u2019s Approval of ORLADEYO\u00ae (berotralstat), the First Oral Therapy for Preventing Hereditary Angioedema (HAE) Attacks in Patients Aged 12 and Older in Colombia<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

BOGOTA, Colombia–(BUSINESS WIRE<\/a>)–Pint Pharma is pleased to announce that the Colombian National Food and Drug Surveillance Institute (INVIMA) has approved ORLADEYO\u00ae, indicated for the prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years of age and older. This milestone represents a significant advancement in expanding access to innovative treatment options for individuals living with HAE across Latin America.<\/p>

\u201cToday\u2019s approval marks another important step in our mission to support patients living with rare diseases throughout Latin America,\u201d said\u00a0David Mu\u00f1oz, CEO of Pint Pharma<\/b>. \u201cBeyond its direct clinical benefits, the availability of ORLADEYO\u00ae in Colombia reflects our ongoing commitment to advancing research and innovation in rare disease treatment.\u201d<\/p>

\u201cThe approval of ORLADEYO\u00ae by INVIMA is excellent news for the hereditary angioedema patient community in Colombia,\u201d added\u00a0Dr. Valnei Canutti, Hematologist and Chief\u00a0<\/b>of<\/b>\u00a0Scientific Affairs at Pint Pharma<\/b>. \u201cThis innovative oral therapy represents a major breakthrough, offering an effective and convenient long-term prophylactic option for preventing HAE attacks.\u201d<\/p>

Mauricio Botero, General Manager of Pint Pharma in Colombia, concluded:\u00a0<\/b>\u201cThis approval is a significant achievement for patients and highlights the strong collaboration between the medical community, the regulatory authorities and the pharmaceutical industry in Colombia to improve treatment options for rare conditions like HAE.\u201d<\/p>

Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of painful and potentially life-threatening swelling of the skin, mucous membranes and internal organs. Until recently, treatment options for HAE were limited, significantly impacting patients\u2019 quality of life and exposing them to the constant risk of unpredictable attacks.<\/p>

About ORLADEYO\u00ae (berotralstat)<\/b><\/p>

ORLADEYO\u00ae is the first and only oral therapy specifically developed to prevent hereditary angioedema (HAE) attacks in adult and pediatric patients aged 12 and older. Taken once daily, ORLADEYO\u00ae works by reducing plasma kallikrein activity, thereby preventing HAE attacks. ORLADEYO\u00ae is a product of BioCryst Pharmaceuticals, Inc., with registration, commercialization and distribution in Latin America exclusively managed by Pint Pharma.<\/p>

About Pint Pharma<\/b><\/p>

Pint Pharma is a specialty pharmaceutical company headquartered in Vienna, Austria, focused on acquiring, licensing and commercializing pharmaceutical products across Latin America. We are a community-driven organization committed to delivering innovative treatments and healthcare solutions through strategic partnerships with global leaders. Our mission is to ensure access, quality and excellence in care for patients across the region.<\/p>

\u00a0<\/p><\/div><\/div><\/div>

Contacts<\/h2>

Jorge Camacho
Chief Strategy Officer
e-mail:\u00a0jorge.camacho@pint-pharma.com<\/a><\/p>

Valnei Canutti
Chief of Scientific Affairs
e-mail:\u00a0valnei.canutti@pint-pharma.com<\/a><\/p><\/div><\/div><\/div>

\u00a0<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Pint Pharma Announces INVIMA\u2019s Approval of ORLADEYO\u00ae (berotralstat), the First Oral Therapy for Preventing Hereditary Angioedema (HAE) Attacks in Patients Aged 12 and Older in Colombia BOGOTA, Colombia–(BUSINESS WIRE)–Pint Pharma is pleased to announce that the Colombian National Food and Drug Surveillance Institute (INVIMA) has approved ORLADEYO\u00ae, indicated for the prophylaxis of hereditary angioedema (HAE) […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1915","post","type-post","status-publish","format-standard","hentry","category-sem-categoria"],"_links":{"self":[{"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/posts\/1915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/comments?post=1915"}],"version-history":[{"count":0,"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/posts\/1915\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/media?parent=1915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/categories?post=1915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/tags?post=1915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}